Details of the Drug Combinations

General Information of This Drug (ID: DMCSGJ2)

Drug Name

BAY1163877 DMCSGJ2

Synonyms

Rogaratinib

Indication

Disease Entry	ICD 11	Status	REF
Bladder cancer	2C94	Phase 2	[1]
Solid tumour/cancer	2A00-2F9Z	Phase 1	[2]
------------------------------------------------------------------------------------

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
BAY1163877 + Bay 80-6946	DCK32U7	Bay 80-6946	Advanced or Metastatic Solid Tumor	[3]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04040725) Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 Overexpression. U.S. National Institutes of Health.
2	ClinicalTrials.gov (NCT01976741) Phase I Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor. U.S. National Institutes of Health.
3	ClinicalTrials.gov (NCT03517956) Phase 1 Study of the Combination of Rogaratinib With Copanlisib in Patients With Fibroblast Growth Factor Receptor (FGFR)-Positive, Locally Advanced or Metastatic Solid Tumors